Bayer gets European Commission nod for Monsanto deal

New Delhi: German chemical and pharma major Bayer today said it has received “conditional” approval from the European Commission for its proposed USD 66 billion acquisition of US-based biotech major Monsanto.

India is among the countries that are yet to give the nod.

Bayer and Monsanto are working closely with the authorities in the US with the goal of closing the transaction in the second quarter of 2018, the company said.

“Receipt of the European Commission’s approval is a major success and a significant milestone, Bayer CEO Werner Baumann said in a statement.

Together with Monsanto, we want to help farmers across the world grow more nutritious food in a more sustainable way that benefits both consumers and the environment,” he said.

According to Bayer, the conditions cover in particular the divestment of certain Bayer businesses, including the global field crop seeds business such as canola, cotton, and soybean (with minor exceptions restricted to the Asia region), the R&D platform for hybrid wheat, the global vegetable seeds business, the global glufosinate ammonium business as well as certain glyphosate-based herbicides in Europe, predominantly for industrial use.

In addition, Monsanto’s global business with the nematicide NemaStrike must be divested.

The conditions also stipulate the transfer of three Bayer research projects in the area of non-selective herbicides and the granting of a license to Bayer’s digital farming portfolio. BASF is the intended purchaser of these assets.

The transaction remains subject to customary closing conditions, including receipt of required regulatory approvals, the company added.

In India, both entities have presence in production and sale of vegetable seeds, cotton seeds as well as in production and sale of non-selective herbicides, according to that notice.

Bayer group is present in India since 1896 and has two divisions — crop science and pharmaceuticals. The group has one listed entity in India — Bayer CropScience Ltd that posted a revenue from operation of nearly Rs 3,000 crore last fiscal.

  • Related Posts

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    India’s $30-billion pharma industry is staring at a fresh challenge after US President Donald Trump announced that generic medicines imported into the US would face tariffs of 100% from Aug…

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    New Delhi: A joint operation by the Delhi Police Crime Branch, the Central Drugs Standard Control Organisation (CDSCO) and the Gautam Buddha Nagar District Drug Department uncovered a suspected illegal…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

    Fake Medicines Worth Over Rs 5 Crore Seized From Factory In Uttarakhand’s Dehradun

    A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

    A ‘Fatal Flaw’ might be lurking in apparently Healthy Heart- Dr Devi Shetty

    CDSCO declares 159 drug samples as NSQs in June

    CDSCO declares 159 drug samples as NSQs in June